LOGO
LOGO

CalciMedica Awaits Acute Pancreatitis Trial Results

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, has a couple of clinical trial events to watch in the coming months.

The lead compound is Auxora, a potent and selective small molecule calcium release activated calcium (CRAC) channel inhibitor. CRAC channels may become hyperactive in specific tissues as a consequence of infection, trauma, or exposure to toxins, leading to cellular damage and death, contributing to a range of diseases.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.